Prostate Cancer Clinical Trials in Cincinnati, Ohio

7 studies are recruiting for prostate cancer in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

   Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Solaris Health - The Urology Group, Cincinnati, Ohio

   Locations

   54 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07005154 on ClinicalTrials.gov

2. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Urology Group - Solaris Network, Cincinnati, Ohio

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

3. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

   The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Hematology Care Incorporated, Cincinnati, Ohio

   Locations

   57 in total

   Run by

   Amgen

   See if you can join NCT04221542 on ClinicalTrials.gov

4. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati, Ohio

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

5. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   36 in total

   Run by

   Janux Therapeutics

   See if you can join NCT05519449 on ClinicalTrials.gov

6. Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)

   Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screenin…

   Stage

   Not phased

   Ages

   22 and older

   Site

   The University of Cinncinatti, Cincinnati, Ohio

   Locations

   2 in total

   Run by

   University of Chicago

   See if you can join NCT06705803 on ClinicalTrials.gov

7. Real World Prostate Cancer Registry

   Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological fe…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cincinnati Cancer Advisors, Cincinnati, Ohio

   Run by

   Cincinnati Cancer Advisors

   See if you can join NCT06355336 on ClinicalTrials.gov